Posted by: Salvatore J. Zambri, founding partner
The AP (7/16) reports, “Irish drug maker Elan Corp. PLC said Thursday it agreed to pay $203.5 million to settle investigations into sales and marketing practices related to the epilepsy drug Zonegran [zonisamide].” Elan’s US division Elan Pharmaceuticals Inc. “expects to plead guilty to a misdemeanor violation of the Food, Drug and Cosmetic Act,” the company said. If the settlement is approved, Elan “said it would resolve all federal and state Medicaid claims into the marketing of Zonegran.”
Patients with epilepsy need drugs, but they deserve to know that the marketing and sales practices of the drug-makers are fair, accurate, and properly informative. Safety and health must be put above profits. It’s a matter of life and death.
Do you have any questions about this post?
About the author:
Mr. Zambri is a Board-Certified Civil Trial Attorney and Past-President of the Trial Lawyers Association of Metropolitan Washington, D.C. He has been acknowledged by Washingtonian magazine as a “Big Gun” and among the “top 1%” of all of the more than 80,000 lawyers in the Washington metropolitan area. The magazine also acknowledged him as “one of Washington’s best–most honest and effective lawyers” who specializes in medical malpractice matters, product liability claims, and serious automobile accident claims. Mr. Zambri has also been repeatedly named a “Super Lawyer” by Law and Politics magazine (2010)–a national publication that honors the top lawyers in America.
Mr. Zambri is regularly asked to present seminars to lawyers and doctors, as well as both medical and law students concerning medication errors, medical malpractice litigation, and safety improvements.
If you have any questions about your legal rights, please email Mr. Zambri at email@example.com or call him at 202-822-1899.